FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Keld Danø

Research Profile

Chemicals & Drugs

Living Beings

Mouse

Anatomy

Genes & Molecular Sequences

Amino Acid Sequences

Concepts & Ideas

Procedures

Disorders

Breast Neoplasms

Co-author Network

Publications

TOP 3
Ole Didrik Laerum; Boye Nielsen; Kjell Ovrebo; Arne Skarstein; Warner Alpízar-Alpízar; Ib Jarle Christensen; Keld Danø; Lars Helgeland; Martin Illemann
Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry.
Charlotte Elberling Almasi; Ib Jarle Christensen; Keld Danø; Hendrik Dienemann; Gunilla Høyer-Hansen; Helle Pappot; Thomas Muley
Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis.
Charlotte Elberling Almasi; Klaus Brasso; Peter Iversen; Helle Pappot; Gunilla Høyer-Hansen; Keld Danø; Ib J Christensen
Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Keld Danø (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Ole Didrik Laerum; Boye Nielsen; Kjell Ovrebo; Arne Skarstein; Warner Alpízar-Alpízar; Ib Jarle Christensen; Keld Danø; Lars Helgeland; Martin Illemann
Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry.
International journal of cancer. Journal international du cancer 2012;131(3):558-69.
2011: Charlotte Elberling Almasi; Ib Jarle Christensen; Keld Danø; Hendrik Dienemann; Gunilla Høyer-Hansen; Helle Pappot; Thomas Muley
Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis.
Lung cancer (Amsterdam, Netherlands) 2011;74(3):510-5.
2011: Charlotte Elberling Almasi; Klaus Brasso; Peter Iversen; Helle Pappot; Gunilla Høyer-Hansen; Keld Danø; Ib J Christensen
Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
The Prostate 2011;71(8):899-907.
2009: Martin Illemann; Nigel Bird; Ali Majeed; Ole D Laerum; Leif R Lund; Keld Danø; Boye Nielsen
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
International journal of cancer. Journal international du cancer 2009;124(8):1860-70.
2008: Ole D Laerum; Martin Illemann; Arne Skarstein; Lars Helgeland; Kjell Ovrebø; Keld Danø; Boye Nielsen
Crohn's disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons.
The American journal of gastroenterology 2008;103(9):2350-8.
2008: Kasper Almholt; Anna Juncker-Jensen; Ole Didrik Laerum; Keld Danø; Morten Johnsen; Leif R Lund; John Rømer
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model.
Molecular cancer therapeutics 2008;7(9):2758-67.
2008: Thore Hillig; Lars H Engelholm; Signe Ingvarsen; Daniel H Madsen; Henrik Gårdsvoll; Jens Knud Larsen; Michael Ploug; Keld Danø; Lars Kjøller; Niels Behrendt
A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
The Journal of biological chemistry 2008;283(22):15217-23.
2007: Beate Heissig; Leif R Lund; Haruyo Akiyama; Makiko Ohki; Yohei Morita; John Rømer; Hiromitsu Nakauchi; Ko Okumura; Hideoki Ogawa; Zena Werb; Keld Danø; Koichi Hattori
The plasminogen fibrinolytic pathway is required for hematopoietic regeneration.
Cell stem cell 2007;1(6):658-70.
2007: Annika Jögi; Jesper Pass; Gunilla Høyer-Hansen; Leif R Lund; Boye Nielsen; Keld Danø; John Rømer
Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice.
Journal of thrombosis and haemostasis : JTH 2007;5(9):1936-44.
2007: Jesper Pass; Annika Jögi; Ida Katrine Lund; Birgitte Rønø; Morten G Rasch; Henrik Gårdsvoll; Leif R Lund; Michael Ploug; John Rømer; Keld Danø; Gunilla Høyer-Hansen
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Thrombosis and haemostasis 2007;97(6):1013-22.
2007: Boye Nielsen; Fritz Rank; Martin Illemann; Leif R Lund; Keld Danø
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
International journal of cancer. Journal international du cancer 2007;120(10):2086-95.
2006: Leif R Lund; Kirsty A Green; Allart A Stoop; Michael Ploug; Kasper Almholt; Jennifer Lilla; Boye Nielsen; Ib Jarle Christensen; Charles S Craik; Zena Werb; Keld Danø; John Rømer
Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
The EMBO journal 2006;25(12):2686-97.
2006: Martin Illemann; Nigel Bird; Ali Majeed; Maxwell Sehested; Ole D Laerum; Leif R Lund; Keld Danø; Boye Nielsen
MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases.
Molecular cancer research : MCR 2006;4(5):293-302.
2006: Timo Piironen; Alexander Haese; Hartwig Huland; Thomas Steuber; Ib Jarle Christensen; Nils Brünner; Keld Danø; Gunilla Høyer-Hansen; Hans Lilja
Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Clinical chemistry 2006;52(5):838-44.
2005: Tanja Xenia Pedersen; Caroline J Pennington; Kasper Almholt; Ib Jarle Christensen; Boye Nielsen; Dylan R Edwards; John Rømer; Keld Danø; Morten Johnsen
Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas.
Carcinogenesis 2005;26(7):1233-40.
2005: Charlotte Elberling Almasi; Gunilla Høyer-Hansen; Ib Jarle Christensen; Keld Danø; Helle Pappot
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Lung cancer (Amsterdam, Netherlands) 2005;48(3):349-55.
2005: Paola Llinas; Marie Hélène Le Du; Henrik Gårdsvoll; Keld Danø; Michael Ploug; Bernard Gilquin; Enrico A Stura; André Ménez
Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
The EMBO journal 2005;24(9):1655-63.
2005: Keld Danø; Niels Behrendt; Gunilla Høyer-Hansen; Morten Johnsen; Leif R Lund; Michael Ploug; John Rømer
Plasminogen activation and cancer.
Thrombosis and haemostasis 2005;93(4):676-81.
2005: Pernille Autzen Usher; Ole Frøkjaer Thomsen; Peter Iversen; Morten Johnsen; Nils Brünner; Gunilla Høyer-Hansen; Peter A Andreasen; Keld Danø; Boye Nielsen
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
International journal of cancer. Journal international du cancer 2005;113(6):870-80.
2005: Kasper Almholt; Leif R Lund; Jørgen Rygaard; Boye Nielsen; Keld Danø; John Rømer; Morten Johnsen
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
International journal of cancer. Journal international du cancer 2005;113(4):525-32.
2004: Thomas J D Jørgensen; Henrik Gårdsvoll; Keld Danø; Peter Roepstorff; Michael Ploug
Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry.
Biochemistry 2004;43(47):15044-57.
2004: Timo Piironen; Birgitte Laursen; Jesper Pass; Karin List; Henrik Gårdsvoll; Michael Ploug; Keld Danø; Gunilla Høyer-Hansen
Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
Clinical chemistry 2004;50(11):2059-68.
2004: Martin Illemann; Ulla Hansen; Hans Jørgen Nielsen; Peter A Andreasen; Gunilla Høyer-Hansen; Leif R Lund; Keld Danø; Boye Nielsen
Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1.
American journal of clinical pathology 2004;122(2):256-65.
2004: Line V Hansen; Henrik Gårdsvoll; Boye Nielsen; Leif R Lund; Keld Danø; Ole N Jensen; Michael Ploug
Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor.
The Biochemical journal 2004;380(Pt 3):845-57.
2004: Henrik Gårdsvoll; Finn Werner; Leif Søndergaard; Keld Danø; Michael Ploug
Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
Protein expression and purification 2004;34(2):284-95.
2004: Lars Kjøller; Lars H Engelholm; Maria Høyer-Hansen; Keld Danø; Thomas H Bugge; Niels Behrendt
uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV.
Experimental cell research 2004;293(1):106-16.
2003: Jesper Pass; Henrik Gårdsvoll; Leif R Lund; Keld Danø; Gunilla Høyer-Hansen
Generation of antibodies to the urokinase receptor (uPAR) by DNA immunization of uPAR knockout mice: membrane-bound uPAR is not required for an antibody response.
Scandinavian journal of immunology 2003;58(3):298-305.
2003: Helene Solberg; Julie Rinkenberger; Keld Danø; Zena Werb; Leif R Lund
A functional overlap of plasminogen and MMPs regulates vascularization during placental development.
Development (Cambridge, England) 2003;130(18):4439-50.
2003: Kasper Almholt; Boye Nielsen; Thomas L Frandsen; Nils Brünner; Keld Danø; Morten Johnsen
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Oncogene 2003;22(28):4389-97.
2003: Tanja Xenia Pedersen; Chidchanop Leethanakul; Vyomesh Patel; David J Mitola; Leif R Lund; Keld Danø; Morten Johnsen; J Silvio Gutkind; Thomas H Bugge
Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma.
Oncogene 2003;22(25):3964-76.
2003: Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
The Biochemical journal 2003;371(Pt 2):277-87.
2003: Lars H Engelholm; Karin List; Sarah Netzel-Arnett; Edna Cukierman; David J Mitola; Hannah Aaronson; Lars Kjøller; Jørgen K Larsen; Kenneth M Yamada; Dudley K Strickland; Kenn Holmbeck; Keld Danø; Henning Birkedal-Hansen; Niels Behrendt; Thomas H Bugge
uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion.
The Journal of cell biology 2003;160(7):1009-15.
2002: Boye Nielsen; Fritz Rank; Lars H Engelholm; Arne Holm; Keld Danø; Niels Behrendt
Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.
International journal of cancer. Journal international du cancer 2002;98(5):656-64.
2002: Michael Ploug; Henrik Gårdsvoll; Thomas J D Jørgensen; L Lønborg Hansen; Keld Danø
Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Biochemical Society transactions 2002;30(2):177-83.
2001: Boye Nielsen; Maxwell Sehested; S Duun; Fritz Rank; S Timshel; Jørgen Rygaard; Morten Johnsen; Keld Danø
Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer.
Laboratory investigation; a journal of technical methods and pathology 2001;81(11):1485-501.
2001: Michael Ploug; Søren ØStergaard; Henrik Gårdsvoll; K Kovalski; C Holst-Hansen; Arne Holm; Liliana Ossowski; Keld Danø
Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.
Biochemistry 2001;40(40):12157-68.
2001: Lars H Engelholm; Boye Nielsen; Sarah Netzel-Arnett; Helene Solberg; X D Chen; J M Lopez Garcia; Carlos Lopez-Otin; M F Young; Henning Birkedal-Hansen; Keld Danø; Leif R Lund; Niels Behrendt; Thomas H Bugge
The urokinase plasminogen activator receptor-associated protein/endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis.
Laboratory investigation; a journal of technical methods and pathology 2001;81(10):1403-14.
2001: Boye Nielsen; Fritz Rank; J M López; M Balbin; F Vizoso; Leif R Lund; Keld Danø; C López-Otín
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Cancer research 2001;61(19):7091-100.
2001: Gunilla Høyer-Hansen; U Pessara; Arne Holm; Jesper Pass; U Weidle; Keld Danø; Niels Behrendt
Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
The Biochemical journal 2001;358(Pt 3):673-9.
2001: John Rømer; C Pyke; Leif R Lund; Elisabeth Ralfkiaer; Keld Danø
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
The Journal of investigative dermatology 2001;116(3):353-8.
2001: Lars H Engelholm; Boye Nielsen; Keld Danø; Niels Behrendt
The urokinase receptor associated protein (uPARAP/endo180): a novel internalization receptor connected to the plasminogen activation system.
Trends in cardiovascular medicine 2001;11(1):7-13.
2000: Agnes N Pedersen; Ib Jarle Christensen; Ross W Stephens; P Briand; Henning T Mouridsen; Keld Danø; Nils Brünner
The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
Cancer research 2000;60(24):6927-34.
2000: Leif R Lund; SF Bjørn; Mark D Sternlicht; Boye Nielsen; Helene Solberg; Pernille Autzen Usher; Ruth Osterby; Ib Jarle Christensen; Ross W Stephens; Thomas H Bugge; Keld Danø; Zena Werb
Lactational competence and involution of the mouse mammary gland require plasminogen.
Development (Cambridge, England) 2000;127(20):4481-92.
2000: Gunilla Høyer-Hansen; MJ Hamers; Agnes N Pedersen; Hans Jørgen Nielsen; Nils Brünner; Keld Danø; Ross W Stephens
Loss of ELISA specificity due to biotinylation of monoclonal antibodies.
Journal of immunological methods 2000;235(1-2):91-9.
2000: Karin List; Ole N Jensen; Thomas H Bugge; Leif R Lund; Michael Ploug; Keld Danø; Niels Behrendt
Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
Biochemistry 2000;39(3):508-15.
2000: Niels Behrendt; Ole N Jensen; Lars H Engelholm; E Mørtz; M Mann; Keld Danø
A urokinase receptor-associated protein with specific collagen binding properties.
The Journal of biological chemistry 2000;275(3):1993-2002.
1999: Henrik Gårdsvoll; Keld Danø; Michael Ploug
Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis.
The Journal of biological chemistry 1999;274(53):37995-8003.
1999: Leif R Lund; J Romer; Thomas H Bugge; Boye Nielsen; Thomas L Frandsen; J L Degen; Ross W Stephens; Keld Danø
Functional overlap between two classes of matrix-degrading proteases in wound healing.
The EMBO journal 1999;18(17):4645-56.
1999: Ross W Stephens; Hans Jørgen Nielsen; Ib Jarle Christensen; O Thorlacius-Ussing; Steen Sørensen; Keld Danø; Nils Brünner
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Journal of the National Cancer Institute 1999;91(10):869-74.
1999: Keld Danø; John Rømer; Boye Nielsen; SF Bjørn; C Pyke; Jørgen Rygaard; Leif R Lund
Cancer invasion and tissue remodeling--cooperation of protease systems and cell types.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 1999;107(1):120-7.
1999: Karin List; Gunilla Høyer-Hansen; E Rønne; Keld Danø; Niels Behrendt
Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology.
Journal of immunological methods 1999;222(1-2):125-33.
1998: Morten Johnsen; Leif R Lund; John Rømer; Kasper Almholt; Keld Danø
Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation.
Current opinion in cell biology 1998;10(5):667-71.
1998: Henrik Gårdsvoll; Anton-Jan van Zonneveld; Arne Holm; Eric Eldering; M van Meijer; Keld Danø; Hans Pannekoek
Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries.
FEBS letters 1998;431(2):170-4.
1998: Thomas H Bugge; Leif R Lund; K K Kombrinck; Boye Nielsen; K Holmbäck; Angela F Drew; Matthew J Flick; David P Witte; Keld Danø; Jay L Degen
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.
Oncogene 1998;16(24):3097-104.
1998: Michael Ploug; S Ostergaard; L B Hansen; Arne Holm; Keld Danø
Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Biochemistry 1998;37(11):3612-22.
1997: Gunilla Høyer-Hansen; Niels Behrendt; Michael Ploug; Keld Danø; K T Preissner
The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
FEBS letters 1997;420(1):79-85.
1997: Boye Nielsen; Maxwell Sehested; Lars Kjeldsen; Niels Borregaard; Jørgen Rygaard; Keld Danø
Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer.
Laboratory investigation; a journal of technical methods and pathology 1997;77(4):345-55.
1997: Ross W Stephens; Agnes N Pedersen; Hans Jørgen Nielsen; MJ Hamers; Gunilla Høyer-Hansen; E Rønne; E Dybkjaer; Keld Danø; Nils Brünner
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.
Clinical chemistry 1997;43(10):1868-76.
1997: SF Bjørn; N Hastrup; Leif R Lund; Keld Danø; J F Larsen; C Pyke
Co-ordinated expression of MMP-2 and its putative activator, MT1-MMP, in human placentation.
Molecular human reproduction 1997;3(8):713-23.
1997: H De Witte; Helle Pappot; Nils Brünner; J Grøndahl-Hansen; G Hoyer-Hansen; Niels Behrendt; B Guldhammer-Skov; Fred C G J Sweep; Th J Benraad; Keld Danø
ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
International journal of cancer. Journal international du cancer 1997;72(3):416-23.
1997: Helle Pappot; Gunilla Høyer-Hansen; E Rønne; H H Hansen; Nils Brünner; Keld Danø; J Grøndahl-Hansen
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
European journal of cancer (Oxford, England : 1990) 1997;33(6):867-72.
1997: Agnes N Pedersen; Gunilla Høyer-Hansen; Nils Brünner; G M Clark; Berthe Larsen; Hans Skovgaard Poulsen; Keld Danø; Ross W Stephens
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
Journal of immunological methods 1997;203(1):55-65.
1997: Niels Behrendt; Keld Danø
Reply to comment on 'Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system' (A. A-R. Higazi)
FEBS letters 1997;402(2-3):293-4.
1997: J Grøndahl-Hansen; Ib Jarle Christensen; P Briand; Helle Pappot; Henning T Mouridsen; Mogens Blichert-Toft; Keld Danø; Nils Brünner
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(2):233-9.
1997: Gunilla Høyer-Hansen; Michael Ploug; Niels Behrendt; E Rønne; Keld Danø
Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
European journal of biochemistry / FEBS 1997;243(1-2):21-6.
1996: Niels Behrendt; Keld Danø
Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
FEBS letters 1996;393(1):31-6.
1996: John Rømer; Thomas H Bugge; C Pyke; Leif R Lund; M J Flick; Jay L Degen; Keld Danø
Plasminogen and wound healing.
Nature medicine 1996;2(7):725.
1996: Boye Nielsen; S Timshel; Lars Kjeldsen; Maxwell Sehested; C Pyke; Niels Borregaard; Keld Danø
92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer.
International journal of cancer. Journal international du cancer 1996;65(1):57-62.
1996: Boye Nielsen; Maxwell Sehested; S Timshel; C Pyke; Keld Danø
Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
Laboratory investigation; a journal of technical methods and pathology 1996;74(1):168-77.
1995: Michael Ploug; H Rahbek-Nielsen; V Ellis; P Roepstorff; Keld Danø
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Biochemistry 1995;34(39):12524-34.
1995: C Pyke; S Salo; Elisabeth Ralfkiaer; John Rømer; Keld Danø; K Tryggvason
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Cancer research 1995;55(18):4132-9.
1995: Leif R Lund; V Ellis; E Rønne; C Pyke; Keld Danø
Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.
The Biochemical journal 1995;310 ( Pt 1)():345-52.
1995: Thomas H Bugge; T T Suh; M J Flick; C C Daugherty; John Rømer; H Solberg; V Ellis; Keld Danø; Jay L Degen
The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility.
The Journal of biological chemistry 1995;270(28):16886-94.
1995: Niels Behrendt; E Rønne; Keld Danø
The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface.
Biological chemistry Hoppe-Seyler 1995;376(5):269-79.
1995: E Rønne; Helle Pappot; J Grøndahl-Hansen; Gunilla Høyer-Hansen; T Plesner; Niels Ebbe Hansen; Keld Danø
The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria.
British journal of haematology 1995;89(3):576-81.
1994: T T Suh; C Nerlov; Keld Danø; Jay L Degen
The murine urokinase-type plasminogen activator receptor gene.
The Journal of biological chemistry 1994;269(42):25992-8.
1994: C Pyke; John Rømer; P Kallunki; Leif R Lund; Elisabeth Ralfkiaer; Keld Danø; K Tryggvason
The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers.
The American journal of pathology 1994;145(4):782-91.
1994: H Solberg; John Rømer; Nils Brünner; A Holm; N Sidenius; Keld Danø; Gunilla Høyer-Hansen
A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
International journal of cancer. Journal international du cancer 1994;58(6):877-81.
1994: H Pedersen; Nils Brünner; D Francis; Kell Osterlind; E Rønne; Heine H Hansen; Keld Danø; J Grøndahl-Hansen
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Cancer research 1994;54(17):4671-5.
1994: Michael Ploug; V Ellis; Keld Danø
Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Biochemistry 1994;33(30):8991-7.
1994: John Rømer; C Pyke; Leif R Lund; J Eriksen; P Kristensen; E Rønne; Gunilla Høyer-Hansen; Keld Danø; Nils Brünner
Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
International journal of cancer. Journal international du cancer 1994;57(4):553-60.
1994: John Rømer; Leif R Lund; J Eriksen; C Pyke; P Kristensen; Keld Danø
The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds.
The Journal of investigative dermatology 1994;102(4):519-22.
1994: E Rønne; Niels Behrendt; Michael Ploug; Hans Jørgen Nielsen; E Wöllisch; U Weidle; Keld Danø; Gunilla Høyer-Hansen
Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay.
Journal of immunological methods 1994;167(1-2):91-101.
1994: H Pedersen; J Grøndahl-Hansen; D Francis; Kell Osterlind; Heine H Hansen; Keld Danø; Nils Brünner
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Cancer research 1994;54(1):120-3.
1994: Nils Brünner; C Pyke; C H Hansen; John Rømer; J Grøndahl-Hansen; Keld Danø
Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer.
Cancer treatment and research 1994;71():299-309.
1993: Niels Behrendt; E Rønne; Keld Danø
A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking.
FEBS letters 1993;336(3):394-6.
1993: V Ellis; Keld Danø
Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.
The Biochemical journal 1993;296 ( Pt 2)():505-10.
1993: H T Myöhänen; Ross W Stephens; K Hedman; H Tapiovaara; E Rønne; Gunilla Høyer-Hansen; Keld Danø; Antti Vaheri
Distribution and lateral mobility of the urokinase-receptor complex at the cell surface.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1993;41(9):1291-301.
1993: Michael Ploug; M Kjalke; E Rønne; U Weidle; Gunilla Høyer-Hansen; Keld Danø
Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins.
The Journal of biological chemistry 1993;268(23):17539-46.
1993: C Pyke; J Eriksen; H Solberg; Boye Nielsen; P Kristensen; Leif R Lund; Keld Danø
An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator.
FEBS letters 1993;326(1-3):69-74.
1993: J Grøndahl-Hansen; Ib Jarle Christensen; C Rosenquist; Nils Brünner; H T Mouridsen; Keld Danø; Mogens Blichert-Toft
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Cancer research 1993;53(11):2513-21.
1993: C Pyke; N Graem; Elisabeth Ralfkiaer; E Rønne; Gunilla Høyer-Hansen; Nils Brünner; Keld Danø
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.
Cancer research 1993;53(8):1911-5.
1993: Niels Behrendt; E Rønne; Keld Danø
Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin.
The Journal of biological chemistry 1993;268(8):5985-9.
1993: V Ellis; Keld Danø
Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation.
The Journal of biological chemistry 1993;268(7):4806-13.
1993: C Pyke; Elisabeth Ralfkiaer; K Tryggvason; Keld Danø
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.
The American journal of pathology 1993;142(2):359-65.
1993: V Ellis; Niels Behrendt; Keld Danø
Cellular receptor for urokinase-type plasminogen activator: function in cell-surface proteolysis.
Methods in enzymology 1993;223():223-33.
1993: Niels Behrendt; Michael Ploug; E Rønne; Gunilla Høyer-Hansen; Keld Danø
Cellular receptor for urokinase-type plasminogen activator: protein structure.
Methods in enzymology 1993;223():207-22.
1992: V Ellis; C Pyke; J Eriksen; H Solberg; Keld Danø
The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.
Annals of the New York Academy of Sciences 1992;667():13-31.
1992: Gunilla Høyer-Hansen; E Rønne; H Solberg; Niels Behrendt; Michael Ploug; Leif R Lund; V Ellis; Keld Danø
Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
The Journal of biological chemistry 1992;267(25):18224-9.
1992: Michael Ploug; J Eriksen; T Plesner; Niels Ebbe Hansen; Keld Danø
A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria.
European journal of biochemistry / FEBS 1992;208(2):397-404.
1992: D Olson; J Pöllänen; Gunilla Høyer-Hansen; E Rønne; K Sakaguchi; T C Wun; E Appella; Keld Danø; F Blasi
Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
The Journal of biological chemistry 1992;267(13):9129-33.
1992: H Solberg; D Løber; J Eriksen; Michael Ploug; E Rønne; Niels Behrendt; Keld Danø; Gunilla Høyer-Hansen
Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.
European journal of biochemistry / FEBS 1992;205(2):451-8.
1992: Leif R Lund; Keld Danø
Okadaic acid strongly increases gene transcription, mRNA and protein level for the urokinase receptor in human A549 cells.
FEBS letters 1992;298(2-3):177-81.
1991: P Kristensen; J Eriksen; F Blasi; Keld Danø
Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.
The Journal of cell biology 1991;115(6):1763-71.
1991: John Rømer; Leif R Lund; J Eriksen; Elisabeth Ralfkiaer; R Zeheb; Thomas D Gelehrter; Keld Danø; P Kristensen
Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds.
The Journal of investigative dermatology 1991;97(5):803-11.
1991: Leif R Lund; John Rømer; E Rønne; V Ellis; F Blasi; Keld Danø
Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells.
The EMBO journal 1991;10(11):3399-407.
1991: Paul H A Quax; Goos N P van Muijen; E J Weening-Verhoeff; L R Lund; Keld Danø; D J Ruiter; Jan H Verheijen
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
The Journal of cell biology 1991;115(1):191-9.
1991: Paul H A Quax; Nina Pedersen; M T Masucci; E J Weening-Verhoeff; Keld Danø; Jan H Verheijen; F Blasi
Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.
Cell regulation 1991;2(10):793-803.
1991: E Rønne; Niels Behrendt; V Ellis; Michael Ploug; Keld Danø; Gunilla Høyer-Hansen
Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.
FEBS letters 1991;288(1-2):233-6.
1991: C Pyke; P Kristensen; Elisabeth Ralfkiaer; J Eriksen; Keld Danø
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
Cancer research 1991;51(15):4067-71.
1991: V Ellis; Niels Behrendt; Keld Danø
Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.
The Journal of biological chemistry 1991;266(19):12752-8.
1991: V Ellis; Keld Danø
Plasminogen activation by receptor-bound urokinase.
Seminars in thrombosis and hemostasis 1991;17(3):194-200.
1991: Michael Ploug; Niels Behrendt; D Løber; Keld Danø
Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator.
Seminars in thrombosis and hemostasis 1991;17(3):183-93.
1991: C Pyke; P Kristensen; Elisabeth Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; Keld Danø
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
The American journal of pathology 1991;138(5):1059-67.
1991: Niels Behrendt; Michael Ploug; L Patthy; G Houen; F Blasi; Keld Danø
The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator.
The Journal of biological chemistry 1991;266(12):7842-7.
1991: Leif R Lund; E Rønne; A L Roldan; Niels Behrendt; John Rømer; F Blasi; Keld Danø
Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells.
The Journal of biological chemistry 1991;266(8):5177-81.
1991: P Kristensen; J Eriksen; Keld Danø
Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1991;39(3):341-9.
1991: Michael Ploug; E Rønne; Niels Behrendt; A L Jensen; F Blasi; Keld Danø
Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol.
The Journal of biological chemistry 1991;266(3):1926-33.
1990: V Ellis; T C Wun; Niels Behrendt; E Rønne; Keld Danø
Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.
The Journal of biological chemistry 1990;265(17):9904-8.
1990: Niels Behrendt; E Rønne; Michael Ploug; Thomas Petri; D Løber; L S Nielsen; Wolf-Dieter Schleuning; F Blasi; E Appella; Keld Danø
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.
The Journal of biological chemistry 1990;265(11):6453-60.
1990: Steen H Hansen; Niels Behrendt; Keld Danø; P Kristensen
Localization of urokinase-type plasminogen activator receptor on U937 cells: phorbol ester PMA induces heterogeneity.
Experimental cell research 1990;187(2):255-62.
1990: A L Roldan; M V Cubellis; M T Masucci; Niels Behrendt; Leif R Lund; Keld Danø; Ettore Appella; F Blasi
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.
The EMBO journal 1990;9(2):467-74.
1990: P Kristensen; C Pyke; Leif R Lund; P A Andreasen; Keld Danø
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Histochemistry 1990;93(6):559-66.
1989: M V Cubellis; P Andreasen; P Ragno; Michael Mayer; Keld Danø; F Blasi
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(13):4828-32.
1989: Ross W Stephens; J Pöllänen; H Tapiovaara; K C Leung; P S Sim; E M Salonen; E Rønne; Niels Behrendt; Keld Danø; Antti Vaheri
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
The Journal of cell biology 1989;108(5):1987-95.
1989: E M Salonen; Antti Vaheri; J Pöllänen; R Stephens; P Andreasen; Michael Mayer; Keld Danø; J Gailit; Erkki Ruoslahti
Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin.
The Journal of biological chemistry 1989;264(11):6339-43.
1989: R Picone; E L Kajtaniak; L S Nielsen; Niels Behrendt; M R Mastronicola; M V Cubellis; Maria Patrizia Stoppelli; S Pedersen; Keld Danø; F Blasi
Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.
The Journal of cell biology 1989;108(2):693-702.
1989: J Eriksen; P Kristensen; C Pyke; Keld Danø
Plasminogen activator inhibitor (type-1) in rat adrenal medulla.
Histochemistry 1989;92(5):377-83.
1989: Birgitte Georg; E Helseth; Leif R Lund; T Skandsen; A Riccio; Keld Danø; G Unsgaard; P A Andreasen
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Molecular and cellular endocrinology 1989;61(1):87-96.
1988: Leif R Lund; Birgitte Georg; L S Nielsen; Michael Mayer; Keld Danø; P A Andreasen
Plasminogen activator inhibitor type 1: cell-specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay.
Molecular and cellular endocrinology 1988;60(1):43-53.
1988: Michael Mayer; Leif R Lund; A Riccio; J Skouv; L S Nielsen; S N Stacey; Keld Danø; P A Andreasen
Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells.
The Journal of biological chemistry 1988;263(30):15688-93.
1988: L C Petersen; L R Lund; L S Nielsen; Keld Danø; L Skriver
One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity.
The Journal of biological chemistry 1988;263(23):11189-95.
1988: J Grøndahl-Hansen; Leif R Lund; Elisabeth Ralfkiaer; V Ottevanger; Keld Danø
Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo.
The Journal of investigative dermatology 1988;90(6):790-5.
1988: Anna Riccio; L R Lund; R Sartorio; A Lania; P A Andreasen; Keld Danø; F Blasi
The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene.
Nucleic acids research 1988;16(7):2805-24.
1988: L S Nielsen; G M Kellerman; Niels Behrendt; R Picone; Keld Danø; F Blasi
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.
The Journal of biological chemistry 1988;263(5):2358-63.
1988: J Pöllänen; K Hedman; L S Nielsen; Keld Danø; Antti Vaheri
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.
The Journal of cell biology 1988;106(1):87-95.
1988: J Grøndahl-Hansen; Niels Agerlin; P Munkholm-Larsen; F Bach; L S Nielsen; Per Dombernowsky; Keld Danø
Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
The Journal of laboratory and clinical medicine 1988;111(1):42-51.
1987: P A Andreasen; C Pyke; A Riccio; P Kristensen; L S Nielsen; Leif R Lund; F Blasi; Keld Danø
Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells.
Molecular and cellular biology 1987;7(8):3021-5.
1987: J Pöllänen; O Saksela; E M Salonen; P Andreasen; L Nielsen; Keld Danø; Antti Vaheri
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.
The Journal of cell biology 1987;104(4):1085-96.
1986: P A Andreasen; Anna Riccio; K G Welinder; R Douglas; R Sartorio; L S Nielsen; C Oppenheimer; F Blasi; Keld Danø
Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing.
FEBS letters 1986;209(2):213-8.
1986: P A Andreasen; L S Nielsen; P Kristensen; J Grøndahl-Hansen; L Skriver; Keld Danø
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
The Journal of biological chemistry 1986;261(17):7644-51.
1986: P A Andreasen; T H Christensen; J Y Huang; L S Nielsen; E L Wilson; Keld Danø
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Molecular and cellular endocrinology 1986;45(2-3):137-47.
1986: L S Nielsen; P A Andreasen; J Grøndahl-Hansen; J Y Huang; P Kristensen; Keld Danø
Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.
Thrombosis and haemostasis 1986;55(2):206-12.
1986: L S Nielsen; P A Andreasen; J Grøndahl-Hansen; L Skriver; Keld Danø
Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass.
FEBS letters 1986;196(2):269-73.
1986: L S Nielsen; J Grøndahl-Hansen; P A Andreasen; L Skriver; Jesper Zeuthen; Keld Danø
Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
Journal of immunoassay 1986;7(3):209-28.
1985: J Grøndahl-Hansen; L S Nielsen; P Kristensen; V Grøndahl-Hansen; P A Andreasen; Keld Danø
Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies.
The British journal of dermatology 1985;113(3):257-63.
1985: V Kielberg; P A Andreasen; J Grøndahl-Hansen; L S Nielsen; L Skriver; Keld Danø
Proenzyme to urokinase-type plasminogen activator in the mouse in vivo.
FEBS letters 1985;182(2):441-5.
1985: Keld Danø; P A Andreasen; J Grøndahl-Hansen; P Kristensen; L S Nielsen; L Skriver
Plasminogen activators, tissue degradation, and cancer.
Advances in cancer research 1985;44():139-266.
1984: L Skriver; L I Larsson; V Kielberg; L S Nielsen; P B Andresen; P Kristensen; Keld Danø
Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.
The Journal of cell biology 1984;99(2):753-7.
1984: P Kristensen; L I Larsson; L S Nielsen; J Grøndahl-Hansen; P A Andreasen; Keld Danø
Human endothelial cells contain one type of plasminogen activator.
FEBS letters 1984;168(1):33-7.
1984: L I Larsson; L Skriver; L S Nielsen; J Grøndahl-Hansen; P Kristensen; Keld Danø
Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse.
The Journal of cell biology 1984;98(3):894-903.
1984: P A Andreasen; L S Nielsen; J Grøndahl-Hansen; L Skriver; Jesper Zeuthen; Ross W Stephens; Keld Danø
Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.
The EMBO journal 1984;3(1):51-6.
1983: L S Nielsen; J G Hansen; P A Andreasen; L Skriver; Keld Danø; Jesper Zeuthen
Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.
The EMBO journal 1983;2(1):115-9.
1983: L Skriver; L S Nielsen; P Kristensen; Keld Danø
[Biochemical mechanism for extracellular proteolysis. Tissue destruction and cancer].
Nordisk medicin 1983;98(10):238-41.
1982: L S Nielsen; J G Hansen; L Skriver; E L Wilson; K Kaltoft; Jesper Zeuthen; Keld Danø
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
Biochemistry 1982;21(25):6410-5.
1982: Keld Danø; E Dabelsteen; L S Nielsen; K Kaltoft; E L Wilson; Jesper Zeuthen
Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1982;30(11):1165-70.
1982: K Kaltoft; L S Nielsen; Jesper Zeuthen; Keld Danø
Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme.
Proceedings of the National Academy of Sciences of the United States of America 1982;79(12):3720-3.
1982: L Skriver; L S Nielsen; R Stephens; Keld Danø
Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus.
European journal of biochemistry / FEBS 1982;124(2):409-14.